303 related articles for article (PubMed ID: 32447601)
1. Non-steroidal anti-inflammatory drugs in patients with stable ankylosing spondylitis receiving tumor necrosis factor inhibitor: continued vs withdrawn.
Park JH; Kwon OC; Park MC
Clin Rheumatol; 2020 Dec; 39(12):3669-3675. PubMed ID: 32447601
[TBL] [Abstract][Full Text] [Related]
2. Impact of Tumor Necrosis Factor Inhibitor Versus Nonsteroidal Antiinflammatory Drug Treatment on Radiographic Progression in Early Ankylosing Spondylitis: Its Relationship to Inflammation Control During Treatment.
Park JW; Kim MJ; Lee JS; Ha YJ; Park JK; Kang EH; Lee YJ; Song YW; Lee EY
Arthritis Rheumatol; 2019 Jan; 71(1):82-90. PubMed ID: 29984487
[TBL] [Abstract][Full Text] [Related]
3. Radiologic parameters of ankylosing spondylitis patients treated with anti-TNF-α versus nonsteroidal anti-inflammatory drugs and sulfasalazine.
Son SM; Choi SH; Shin JK; Goh TS; Lee JS
Eur Spine J; 2019 Apr; 28(4):649-657. PubMed ID: 30742244
[TBL] [Abstract][Full Text] [Related]
4. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
[TBL] [Abstract][Full Text] [Related]
5. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
[TBL] [Abstract][Full Text] [Related]
6. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
7. [Relapse of ankylosing spondylitis and its predictors after withdrawal of tumor necrosis factor-α inhibitors: a 52-week follow-up study].
Tang C; Chen F; Zheng S; Wu L; Chen S; Zhu J; Li J
Nan Fang Yi Ke Da Xue Xue Bao; 2021 May; 41(5):633-639. PubMed ID: 34134948
[TBL] [Abstract][Full Text] [Related]
8. Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study.
Nam B; Koo BS; Lee TH; Shin JH; Kim JJ; Lee S; Joo KB; Kim TH
BMC Musculoskelet Disord; 2021 Feb; 22(1):140. PubMed ID: 33541326
[TBL] [Abstract][Full Text] [Related]
9. Maintained activity in ankylosing spondylitis patients treated with TNFi and/or NSAID for at least 12 weeks: a cross-sectional study in Brazil.
de Toledo RA; Grizzo FMF; Fernandes V; Calheiros R; Russo RT; Rosal G; Marchese LRD; Tunala R; Watanabe R; Birck MG; Julian GS; Forestiero FJ
Adv Rheumatol; 2022 Oct; 62(1):38. PubMed ID: 36307836
[TBL] [Abstract][Full Text] [Related]
10. Predictive Values of Blood Type I and Type II Interferon Production for Disease Activity and Clinical Response to TNF-α Blocking Therapy in Patients with Ankylosing Spondylitis.
Hu Y; Lou B; Jiang Z; Yu C
Tohoku J Exp Med; 2023 Jul; 260(3):263-271. PubMed ID: 37081619
[TBL] [Abstract][Full Text] [Related]
11. Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis.
Braun J; Baraliakos X; Kiltz U; Krüger K; Burmester GR; Wassenberg S; Thomas MH
J Rheumatol; 2020 Jan; 47(1):35-41. PubMed ID: 30877206
[TBL] [Abstract][Full Text] [Related]
12. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
Kim Y; Park S; Kim HS
Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
[TBL] [Abstract][Full Text] [Related]
13. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
[TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.
Wang R; Dasgupta A; Ward MM
J Rheumatol; 2018 Apr; 45(4):481-490. PubMed ID: 29335342
[TBL] [Abstract][Full Text] [Related]
15. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
16. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
Maksymowych WP; Jhangri GS; Fitzgerald AA; LeClercq S; Chiu P; Yan A; Skeith KJ; Aaron SL; Homik J; Davis P; Sholter D; Russell AS
Arthritis Rheum; 2002 Mar; 46(3):766-73. PubMed ID: 11920413
[TBL] [Abstract][Full Text] [Related]
17. Relationship Between Inflammation and Radiographic Progression in Patients With Ankylosing Spondylitis Attaining a BASDAI of Less Than 4 During Tumor Necrosis Factor Inhibitor Treatment.
Koo BS; Oh JS; Park SY; Shin JH; Nam B; Lee S; Joo KB; Kim TH
J Rheumatol; 2022 Dec; 49(12):1328-1334. PubMed ID: 35840153
[TBL] [Abstract][Full Text] [Related]
18. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.
Pham T; Landewé R; van der Linden S; Dougados M; Sieper J; Braun J; Davis J; Rudwaleit M; Collantes E; Burgos-Vargas R; Edmonds J; Olivieri I; van der Horst-Bruinsma I; Mielants H; Stone M; Emery P; van der Heijde D
Ann Rheum Dis; 2006 Dec; 65(12):1620-5. PubMed ID: 16464984
[TBL] [Abstract][Full Text] [Related]
19. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
Michielsens CAJ; den Broeder N; Mulder MLM; van den Hoogen FHJ; Verhoef LM; den Broeder AA
Rheumatology (Oxford); 2022 May; 61(6):2307-2315. PubMed ID: 34599803
[TBL] [Abstract][Full Text] [Related]
20. Effects of nonsteroidal anti-inflammatory drugs on serum proinflammatory cytokines in the treatment of ankylosing spondylitis.
Yan Y; Guo TM; Zhu C
Biochem Cell Biol; 2018 Aug; 96(4):450-456. PubMed ID: 29324184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
